Nuclear medicine diagnostic techniques in the era of pathophysiology-based csf biomarkers for Alzheimers Disease

Journal of Alzheimer's Disease

Volumn 26, Issue SUPPL. 3, 2011, Pages 97-103

  Weih, Markus ^a   Degirmenci, Ümüt ^a   Kreil, Sebastian ^a   Suttner, Gerald ^a   Schmidt, Daniela ^a   Kornhuber, Johannes ^a   Lewczuk, Piotr ^a   Kuwert, Torsten ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CEREBROSPINAL FLUID; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIN LABELING;

EID: 80055041329     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-0020     Document Type: Article

References (48)

1. Knopman D, DeKosky S, Cummings J, Chui H, Corey-Bloom J, Relkin N, Small G, Miller B, Stevens J (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153. (Pubitemid 32405708)
2. Launes J, Sulkava R, Erkinjuntti T, Nikkinen P, Lindroth L, Liewendahl K, Iivanainen M (1991) 99Tcm-HMPAO SPECT in suspected dementia. Nucl Med Commun 12, 757-765.
3. Dougall NJ, Bruggink S, Ebmeier KP (2004) Systematic reviewof the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 12, 554-570. (Pubitemid 41031058)
4. Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, Samuraki M, Yanase D, Yoshita M, Iwasa K, Mastunari I, Yamada M (2010) A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimers disease in a memory clinic. Dement Geriatr Cogn Disord 30, 285-292.
5. Weih M, Krinninger M, Zimmermann R, Lewczuk P, Svitek J, Schaller G, Degirmenci U, Richter-Schmidinger T, Wiltfang J, Kuwert T, Kornhuber J, Schmidt D (2009) Sensitivität der neurochemischen Demenzdiagnostik im Liquor im Vergleich zur 99mTc-SPECT bei Alzheimer Demenz. Fortschr Neurol Psychiatr 77, 407-411.
6. Schmidt D, Zimmermann R, Lewczuk P, Schaller G, Degirmenci U, Kreil S, Wiltfang J, Kuwert T, Kornhuber J, Weih M (2010) Confirmation rate of blinded (99 m)Tc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease. J Neural Transm 117, 1111-1114.
7. Bonte FJ, Weiner MF, Bigio EH, White CL 3rd (1997) Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 202, 793-797. (Pubitemid 27093456)
8. Jagust W, Thisted R, Devous MD Sr, Van Heertum R, Mayberg H, Jobst K, Smith AD, Borys N (2001) SPECT perfusion imaging in the diagnosis of Alzheimers disease: a clinical-pathologic study. Neurology 56, 950-956. (Pubitemid 32290814)
9. Hu WT,Wang Z, Lee VM, Trojanowski JQ, Detre JA, Grossman M (2010) Distinct cerebral perfusion patterns in FTLD and AD. Neurology 75, 881-888.
10. Paiva FF, Tannus A, Silva AC (2007) Measurement of cerebral perfusion territories using arterial spin labelling. NMR Biomed 20, 633-642. (Pubitemid 350120243)
11. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234, 851-859. (Pubitemid 40250829)
12. DuAT, Jahng GH, Hayasaka S, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin KP, Miller BL, Weiner MW, Schuff N (2006) Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 67, 1215-1220. (Pubitemid 44563830)
13. Xu G, Rowley HA, Wu G, Alsop DC, Shankaranarayanan A, Dowling M, Christian BT, Oakes TR, Johnson SC (2010) Reliability and precision of pseudo-continuous arterial spin labeling perfusion MRI on 3.0 T and comparison with 15Owater PET in elderly subjects at risk for Alzheimers disease. NMR Biomed 23, 286-293.
14. Farkas T, Ferris SH, Wolf AP, De Leon MJ, Christman DR, ReisbergB, Alavi A, Fowler JS, George AE, ReivichM(1982) 18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. Am J Psychiatry 139, 352-353. (Pubitemid 12180193)
15. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT (2004) Alzheimer disease: operating characteristics of PET-a meta-analysis. Radiology 231, 73-80. (Pubitemid 38375412)
16. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimers disease. Ann Neurol 38, 643-648.
17. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J (2004) Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimers disease: original data and reviewof the literature. J Mol Neurosci 23, 115-122. (Pubitemid 41359194)
18. Wiltfang J, Lewczuk P, Riederer P, Grunblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K (2005) Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 6, 69-84. (Pubitemid 40895131)
19. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimers disease. Lancet Neurol 2, 605-613. (Pubitemid 37162569)
20. Mitchell A (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimers disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80, 966-975.
21. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimers dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25, 273-281.
22. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J (2009) Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 116, 1163-1167.
23. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S, van der Flier W, Blankenstein M, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser P, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen M, Minthon L,Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
24. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimers disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)
25. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L,Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimers disease: a multicenter study. Mol Psychiatry 15, 138-145.
26. KlunkW, Engler H, Nordberg A,Wang Y, Blomqvist G, Holt D, Bergström M, Savitcheva I, Huang G, Estrada S, Ausen B, Debnath M, Barletta J, Price J, Sandell J, Lopresti B, Wall A, Koivisto P, Antoni G, Mathis C, Langström B (2004) Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319. (Pubitemid 38269583)
27. Roe C, Mintun M, Ghoshal N, Williams M, Grant E, Marcus D, Morris J (2010) Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. Neurology 75, 42-48.
28. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O (2010) Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 74, 121-127.
29. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66, 1469-1475.
30. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ (2010) 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68, 319-329.
31. Vardy ER, Langheinrich T, Hinz R, Snowden JS, Gerhard A, Richardson AM, Neary D, Anton J, Brown GD, Herholz K (2010) POD14 Amyloid PET using 18F-AV-45 in Alzheimers disease and frontotemporal dementia: first UK results. J Neurol Neurosurg Psychiatry 81, e45.
32. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355, 2652-2663. (Pubitemid 44969124)
33. McNeill R, Sare GM, Manoharan M, Testa HJ, Mann DM, Neary D, Snowden JS, Varma AR (2007) Accuracy of singlephoton emission computed tomography in differentiating frontotemporal dementia from Alzheimers disease. J Neurol Neurosurg Psychiatry 78, 350-355. (Pubitemid 46580539)
34. Mendez MF, Shapira JS, McMurtray A, Licht E, Miller BL (2007) Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol 64, 830-835. (Pubitemid 46919837)
35. Shimizu S, Hanyu H, Kanetaka H, Iwamoto T, Koizumi K, Abe K (2005) Differentiation of dementia with Lewy bodies from Alzheimers disease using brainSPECT. Dement Geriatr Cogn Disord 20, 25-30. (Pubitemid 40981174)
36. Goto H, Ishii K, Uemura T, Miyamoto N, Yoshikawa T, Shimada K, Ohkawa S (2010) Differential diagnosis of dementia with Lewy bodies and Alzheimer disease using combined MR imaging and brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol 31, 720-725.
37. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC,Wolters EC (1998) Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy- 3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinsons disease. J Nucl Med 39, 1143-1148. (Pubitemid 28326141)
38. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R et al. (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimers disease. Ann Neurol 38, 643-648.
39. Zeintl J, Vija AH, Yahil A, Hornegger J, Kuwert T (2010) Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. J Nucl Med 51, 921-928.
40. Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mosch D, Schad D, Schwaiger M,KurzA(1997) Quantitative assessment of cerebral blood flowin patients with Alzheimers disease by SPECT. J Nucl Med 38, 1095-1101. (Pubitemid 27339617)
41. Signorini M, Paulesu E, Friston K, Perani D, Colleluori A, Lucignani G, Grassi F, Bettinardi V, Frackowiak RS, Fazio F (1999) Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative 18FFDG PET:Aclinical validation of statistical parametric mapping. Neuroimage 9, 63-80. (Pubitemid 29369342)
42. Pagani M, Salmaso D, Rodriguez G, Nardo D, Nobili F (2009) Principal component analysis in mild and moderate Alzheimers disease-a novel approach to clinical diagnosis. Psychiatry Res 173, 8-14.
43. Merhof D, Markiewicz PJ, Platsch G, Declerck J, Weih M, Kornhuber J,Kuwert T, Matthews JC, HerholzK(2010) Optimized data preprocessing for multivariate analysis applied to (99 m)Tc-ECD SPECT data sets of Alzheimers patients and asymptomatic controls. J Cereb Blood Flow Metab.
44. Luckhaus C, Cohnen M, Fluss MO, Janner M, Grass-Kapanke B, Teipel SJ, Grothe M, Hampel H, Peters O, Kornhuber J, Maier W, Supprian T, Gaebel W, Modder U, Wittsack HJ (2010) The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimers dementia. Psychiatry Res 183, 44-51.
45. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet 358, 461-467. (Pubitemid 32769854)
46. Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, MathisCA(2009) Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 66, 60-67.
47. Tsolaki M, Sakka V, Gerasimou G, Dimacopoulos N, Chatzizisi O, Fountoulakis KN, Kyriazis G, Papanastasiou J, Kazis A (2001) Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimers type, other types of dementia, and control subjects. Am J Alzheimers Dis Other Dement 16, 21-31. (Pubitemid 32127147)
48. Colloby SJ, Perry EK, Pakrasi S, Pimlott SL, Wyper DJ, McKeith IG,Williams ED, OBrien JT (2010) Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimers disease and dementia with Lewy bodies. Am J Geriatr Psychiatry 18, 86-90.